Nasdaq · CIK 0001626971
CRVS Corvus Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Dec 8, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at Corvus Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | Peter A. Thompson director, owner sell | $4.9M 1,176,332 shares | -14% | - | |
| 53Moderate | Orbimed Advisors LLC director, owner sell | $4.9M 1,176,332 shares | -14% | - |
Transactions
The last 20 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 4, 2025 | Jeffrey Arcara Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Dec 8, 2025 |
| Jun 27, 2025 | Peter A. Thompson director, owner | XIn-the-money exercise Common Stockindirect: See Footnotes | +1,397,684 | $3.50 | $4.9M | 8,341,338 | Jul 1, 2025 |
| Jun 27, 2025 | Orbimed Advisors LLC director, owner | XIn-the-money exercise Common Stockindirect: See Footnotes | +1,397,684 | $3.50 | $4.9M | 8,341,338 | Jul 1, 2025 |
| Jun 27, 2025 | Peter A. Thompson director, owner | SOpen-market sale Common Stockindirect: See Footnotes | -1,176,332 | $4.16 | $4.9M | 7,165,006 | Jul 1, 2025 |
| Jun 27, 2025 | Orbimed Advisors LLC director, owner | SOpen-market sale Common Stockindirect: See Footnotes | -1,176,332 | $4.16 | $4.9M | 7,165,006 | Jul 1, 2025 |
| Jun 27, 2025 | Peter A. Thompson director, owner | XIn-the-money exercise Common Warrants (right to buy)derivativeindirect: See Footnotes | -1,397,684 | $0.00 | $0 | 0 | Jul 1, 2025 |
| Jun 27, 2025 | Orbimed Advisors LLC director, owner | XIn-the-money exercise Common Warrants (right to buy)derivativeindirect: See Footnotes | -1,397,684 | $0.00 | $0 | 0 | Jul 1, 2025 |
| Jun 12, 2025 | Linda Grais director | AGrant or award Stock Option (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 16, 2025 |
| Jun 12, 2025 | Scott W Morrison director | AGrant or award Stock Option (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 16, 2025 |
| Jun 12, 2025 | Peter A. Thompson director, owner | AGrant or award Stock Option (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 16, 2025 |
| Jun 12, 2025 | Ian T Clark director | AGrant or award Stock Option (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 16, 2025 |
| Jun 4, 2025 | William Benton Jones See Remarks | MOption exercise Common Stock | +19,357 | $3.50 | $68k | 173,130 | Jun 6, 2025 |
| Jun 4, 2025 | William Benton Jones See Remarks | MOption exercise Warrant (Right to Buy)derivative | -19,357 | - | - | 0 | Jun 6, 2025 |
| May 7, 2025 | Richard A Miller Md President and CEO | MOption exercise Common Stock | +559,073 | $3.50 | $2.0M | 1,136,707 | May 9, 2025 |
| May 7, 2025 | Richard A Miller Md President and CEO | MOption exercise Warrant (Right to Buy)derivative | -559,073 | - | - | 0 | May 9, 2025 |
| Apr 8, 2025 | Richard van den Broek director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Apr 9, 2025 |
| Dec 20, 2024 | Jeffrey Arcara Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Dec 23, 2024 |
| Dec 20, 2024 | Richard A Miller Md President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Dec 23, 2024 |
| Dec 20, 2024 | Leiv Lea Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Dec 23, 2024 |
| Dec 20, 2024 | William Benton Jones See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Dec 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jeffrey ArcaraChief Business Officer
- Ian T Clarkdirector
- Linda Graisdirector
- William Benton JonesSee Remarks
- Leiv LeaChief Financial Officer
- Richard A Miller MdPresident and CEO
- Scott W Morrisondirector
- Orbimed Advisors LLCdirector, owner
- Peter A. Thompsondirector, owner
- Richard van den Broekdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.